2003•European NeuropsychopharmacologyRequires access

P.1.127 The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline

Sheldon Preskorn, Rehmat Shah, Beryl Silkey, MELISSA NEFF, Amanda L. Golbeck, Jin‐Seok Choi

Open publisher page 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Paroxetine, Fluoxetine, Sertraline, Drug, Pharmacology, Medicine, Drug-drug interaction, CYP2D6

Back to paper search Browse research topics Original source

P.1.127 The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline — Research Paper | ScholarLens